BG
MRTX

Bollard Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bollard Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,600
Closed -$1.28M – 425
2022
Q1 		$1.28M Buy
+15,600
New +$1.6M 0.04% 130

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bollard Group's MRTX Position: Q2 2022 in Review

Bollard Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 15,600 shares — an estimated $1.28M sold.

Bollard Group first reported a position in MRTX in Q1 2022 and held it in 1 quarter. The position peaked at $1.28M in Q1 2022. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Bollard Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 15,600 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.28M.
  • Bollard Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Bollard Group's Mirati Therapeutics, Inc. Common Stock position peaked at $1.28M in Q1 2022.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.